Navigation Links
Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program
Date:10/14/2009

unct to existing wound care therapies, such as debridement. Since collagen has been approved by the FDA as a medical device, Cardium intends to a develop a registration pathway for its collagen to be used in conjunction with debridement, which is typically applied as standard of care for all diabetic foot ulcers and many other types of soft tissue wounds. As announced today, the Company plans to advance this collagen-based product termed Excellagen(TM) along an abbreviated 510(k) registration process in consultation with the FDA.

Following completion of safety and preliminary efficacy data, the Company also plans to schedule a meeting with the FDA to review the complete integrated data set and outline plans for a Phase 3 clinical study program designed to confirm the safety and effectiveness of Excellarate as compared to standard of care, since PDGF-B is known to contribute to the biologic process of wound healing and is itself an approved protein product for use in advanced wound care. The Company believes that the combination of collagen and PDGF-B as provided by the Excellarate product candidate holds the potential to further promote wound healing in non-healing diabetic foot ulcers and other difficult-to-treat wounds. Based on feedback from study investigators, and with the additional positive safety data from the Phase 2b study, the Phase 3 program is also expected to allow for one or two follow-up doses in patients that exhibit a slower healing rate or who have not yet achieved substantial closure following the initial administration of product.

Regranex® (becaplermin, 0.01%) is a PDGF-B protein therapy that is currently the only FDA-approved advanced care biologic for the treatment of patients with lower extremity neuropathic diabetic foot ulcers. PDGF-B protein-based therapy is a daily use prescription medication for treatment for up to 20 weeks, which would require up to 140 daily administrations of product and an additional
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers
2. Scientific Journal Gene Therapy Reports That Cardiums Gene Activated Matrix Technology Accelerates Periodontal Tissue Regeneration
3. Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments
4. Cardium Completes Sale of InnerCool Therapies Business to Royal Philips Electronics
5. Cardium Receives Preliminary Notification of Inclusion in the Russell 3000(R) Index and Russell Global(R) Index
6. Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
7. Cardium Reports on First Quarter 2009 Financial Results and Recent Developments
8. Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
9. Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE Amex
10. Cardiums InnerCool Announces Journal of Neurotrauma Highlights Hypothermia Therapys Role in Post Cardiac Arrest, and Traumatic Brain and Spinal Cord Injury Patients
11. Cardium Reports on Recent Highlights, Financial Results and 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... According to WFLA on July 16th, Sarasota has seen at least ... deaths have held steady over the last “couple of months” according to WFLA. Law ... spurred by the crackdown of prescription painkillers. Many users who were addicted to prescription ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Practice, and Hospital Medicine Practice, is pleased to announce that it has partnered ... application format available on iPhones, iPads, and Android smartphones and tablets. , ...
(Date:7/31/2015)... ... 2015 , ... An article entitled " Dentists Doing Dermatology? ... unfortunate experience having cosmetic skin procedures done by a family doctor not board-certified ... bruising, and pain. This woman’s experience is only one in a series of ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... of a wide variety of nutritional and wellness products, announced the addition of ... specializes in massage therapy, active isolated stretching and the prevention and rehabilitation of ...
(Date:7/31/2015)... ... 31, 2015 , ... People love to feel like they ... price is an important factor to clients when choosing to purchase a policy. ... Preferred Producer Multi-Life Discount program, where advisers pass savings onto their clients. , ...
Breaking Medicine News(10 mins):Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Secura Consultants Gives Advisers Competitive New Edge with Multi-Life Discount Program 2
... fear and anxiety are involved, and the amygdalathe brain,s almond-shaped ... But the amygdala doesn,t do its job alone. Scientists at ... the fear map to part of the brain known as ... MD, PhD, found that mice lacking a critical growth factor ...
... scientists at Carnegie Mellon University,s Language Technologies Institute (LTI) ... on Haitian Creole so that translation tools desperately needed ... earthquake-ravaged island can be rapidly developed. Since Carnegie Mellon ... a team at Microsoft Research has used it to ...
... ... ... HealthWorks Medical Group, a leading nationwide operator of on-the-job-injury health and urgent care centers, today ... by getting workers vaccinated against H1N1., , , , ,“U.S. HealthWorks wants to send our ...
... mice ,rejuvenated, when treated with blood factors from younger mice, ... have found a way to make old stem cells in ... could lead to ways to slow the aging process. , ... putting them in old mice made old stem cells take ...
... stem cell therapy, but much research remains to be ... at Stanford University have succeeded in creating brain nerve ... tails of adult mice. , The new approach could ... how cells choose and maintain their specialized roles in ...
... ... Vice Chairwoman, Stephanie DeKemper takes ownership. , ... Indianapolis, IN (PRWEB) Jan. 27, 2010 -- SynCare, LLC ( www.syncarellc.com ) announced ... of Directors Vice Chairwoman Stephanie DeKemper. , , , , ,An aggressive and well-respected consumer ...
Cached Medicine News:Health News:Brain scientists extend map of fear memory formation 2Health News:Carnegie Mellon releases data on Haitian Creole to hasten development of translation tools 2Health News:Twitter Contest: Free, Onsite H1N1 Vaccination Day for Winning Businesses 2Health News:Aging of Blood Stem Cells May Be Reversible 2Health News:Scientists Turn Mouse Skin Cells Into Nerve Cells 2Health News:Scientists Turn Mouse Skin Cells Into Nerve Cells 3Health News:SynCare, LLC Completes Sale of Assets to Stephanie DeKemper 2Health News:SynCare, LLC Completes Sale of Assets to Stephanie DeKemper 3
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... PLAINFIELD, N.J., July 30, 2015 PTC Therapeutics, ... update and reported financial results for the second quarter ... progressing on many fronts across the organization.  We are ... Duchenne muscular dystrophy clinical trial ever conducted with topline ... Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna ...
(Date:7/30/2015)... 2015  Growth of the U.S. nonprescription market is ... prescription users to the OTC market. Due to an ... Rx-to-OTC switch activity over the next five years with ... new brands entering the market into existing categories. ... years (even those with low to moderate likelihood), the ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... builds on company,s suite of tests to evaluate ... a leading clinical-diagnostics and biomedical-research laboratory specializing in ... diagnostic assay designed to help physicians better understand ... The company will introduce the Pneumococcal Antibody ...
... March 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") ... it has started patient enrolment in a Phase ... in combination with paclitaxel and carboplatin in patients ... or EGFR-activated tumours. The Principal Investigator is Dr. ...
Cached Medicine Technology:IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729 2Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2
... Microalbumin Strips provide albumin, creatinine and albumin-to-creatinine ... Microalbumin product is useful to test for ... in order to detect early kidney disease. ... the urinary albumin excretion rate, is an ...
... to near-patient urinalysis. The Chemstrip ... affordable, reliable alternative to visual ... fundamental, easy-to-use features, the Chemstrip ... office lab, clinic, and hospital ...
... UA is the first hand-held urine ... valuable lab bench space. Automation of ... in results between operators and transcription ... run, corrects for ambient temperature and ...
... first outside-the-balloon, dual-wire dilatation catheter. The ... innovative new approach to dilatation. Its unique, ... wires to create expansion planes at low ... ,The FX miniRAIL RX PTCA Catheter is ...
Medicine Products: